Drone assault devastates Indian‑linked pharma complex
New Delhi. A Russian‑controlled drone struck the Kusum Group’s manufacturing site in Sumy, Ukraine, reducing the main structure to rubble, killing an engineer and wounding several employees. Multiple impact points shattered the engineering wing and forced an immediate evacuation of the premises.
Early estimates put the financial hit at around Rs 400 crore, though the company says a comprehensive audit is still pending. The scale of the damage means the plant will likely stay shut for an undefined period.
Indian origins, Ukrainian footprint
Since entering the Ukrainian market in 1994 as a distributor of Indian medicines, the Kusum Group expanded its footprint by erecting a full‑scale production hub in Sumy in 2009, complementing its 2007 manufacturing base in India. Today the group produces more than 50 generic formulations and supplies pharmacies across Ukraine, Uzbekistan, Kazakhstan and the Philippines, positioning itself as a Ukrainian pharma player with Indian roots.
Operations continued despite conflict – until now
Even as fighting persisted, the Sumy facility kept manufacturing essential drugs for local patients and neighboring markets. The latest drone strike, however, has brought production to a standstill and prompted senior managers to consider relocating vulnerable lines back to India.
Ukrainian President Volodymyr Zelenskyy denounced the attack, confirming that a drone barrage targeted the pharmaceutical complex and resulted in a fatality. The episode highlights the growing peril faced by civilian and commercial assets in active war zones.
Broader consequences for drug supply chains
The loss of the Sumy plant jeopardizes the availability of key generic medicines in the region and raises serious questions about the durability of cross‑border supply chains amid armed conflict. A thorough post‑incident review will quantify the true economic and operational impact on the Indian‑linked conglomerate.
